Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Vertex Pharmaceuticals has multiple growth drivers with potentially more on the way. Yo-yos are fun for kids. But yo-yo stock ...

Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close.

As the U.S. stock market navigates a period of heightened volatility, with major indexes experiencing significant fluctuations amid tariff discussions and economic uncertainties, investors are keenly ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Of course, Vertex's success didn't happen overnight -- and the company even had to quickly shift focus after its initial drug, a hepatitis C treatment, didn't deliver lasting growth. Contrary to ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...